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[Abstract] Objective: To investigate the dose difference of Compass three-dimensional (3D) dose verification 
system in the dose verification of volumetric modulated arc therapy (VMAT) planning for nasopharyngeal carcinoma 
(NPC), and to analyze the reasons of dose difference. Methods: 17 patients with NPC were selected. VMAT planning 
was formulated on Monaco and was transmitted to Compass. Both computerized dose (CD) that was calculated by 
Compass and reconstructed dose (RD) that was actual measured were used to verify the series of parameters included 
γ-ray pass rate, D1%, D99% and Dmean at target region and organ at risk (OAR). Results: All of γ-ray pass rates of TPS-
CD were higher than 97.5% and those of TPS-RD were higher than 95%, respectively. And γ-ray pass rate of each 
item of TPS-CD was significantly higher than that of TPS-RD (t=2.110, t=2.749, t=2.489, t=2.687, t=2.798, t=2.881, 
t=2.921, P<0.05). While the differences of OAR between the two results were no significant. The each absolute dose 
difference of D1%, Dmean and D99% of target region between TPS and RD was less than 200 cGy, and the percentage 
difference of each absolute dose difference was less than 2.5%, and the difference of them between TPS and RD was 
no significant. And the differences of dose of above 3 indicators of left and right crystalline lens between TPS and RD 
were significant (t=4.328, t=4.658, t=4.210, t=4.511, t=4.896, t=5.241, P<0.001). The differences of D99% of OARs 
included spinal cord, brainstem, left and right parotid gland between TPS and RD was significant(t=4.018, t=4.035, 
t=3.646, t=4.112, P<0.05), while that of Dmean and D1% between TPS and RD were no significant, respectively. 
Conclusion: The compass 3D dose verification system can directly and rapidly analyze the dose differences of target 
region and OAR between theoretical radiation and actual radiation in VMAT planning dose verification, and can 
provide data support for the precise implementation of dose. 
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容积旋转调强放射治疗(volumetric modulated 
arc therapy，VMAT)是近年来发展起来的一种新















































脑干＜54 Gy，腮腺D50＜35 Gy，眼晶状体＜7 Gy，




































ROI   TPS-CD(%)   TPS-RD(%) t值 P值
GTVnx-P 98.9±0.43 96.1±2.55 2.110 0.049
CTV1-P 99.1±0.52 97.2±2.13 2.749 0.016
CTV2-P 98.8±0.39 96.3±1.93 2.489 0.038
GTVnd-L-P 97.6±1.53 95.1±3.15 2.687 0.018
CTVnd-L-P 98.1±0.95 95.9±2.89 2.798 0.017
GTVnd-R-P 97.9±1.49 95.2±2.63 2.881 0.015
CTVnd-R-P 98.0±1.61 95.6±2.11 2.921 0.010
脊髓 98.3±1.67 98.2±1.33 1.337 0.201
脑干 99.3±0.48 98.6±0.42 1.116 0.309
左腮腺 98.6±1.23 96.9±1.85 1.411 0.192
右腮腺 97.8±1.31 96.3±2.16 1.651 0.115
左晶状体 99.8±0.09 99.7±0.13 0.681 0.508
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表2 靶区和OAR的TPS-RD绝对剂量比较(x-±s)
ROI 指标 TPS(cGy) RD(cGy)
差值 TPS-RD
绝对值 百分比 t值 P值
GTVnx-P
D1% 7700.1±124.9 7614.9±141.9 85.5±40.3 1.11±0.63 0.161 0.812
Dmean 7461.3±159.9 7356.6±110.6 104.7±38.3 1.40±0.41 1.322 0.549
D99% 7142.2±130.4 7056.2±145.3 85.0±39.1 1.19±0.54 1.286 0.551
CTV1-P
D1% 7558.6±143.2 7494.2±152.7 64.4±50.6 0.84±0.43 0.171 0.809
Dmean 7099.4±109.6 7006.6±89.6 92.8±63.3 1.31±0.34 1.283 0.564
D99% 6415.3±100.7 6325.2±110.3 90.1±42.1 1.40±0.44 1.396 0.405
CTV2-P
D1% 7218.6±159.6 7100.2±171.7 118.4±61.3 1.64±0.43 1.411 0.355
Dmean 6472.3±111.3 6400.6±100.4 92.8±72.6 1.11±0.38 0.999 0.682
D99% 5338.3±98.4 5252.2±95.6 86.1±62.1 1.61±0.29 1.336 0.522
GTVnd-L-P
D1% 7146.8±169.3 7009.3±158.6 137.5±51.6 1.92±0.33 1.423 0.348
Dmean 6808.8±106.1 6720.2±80.2 88.6±61.7 1.30±0.41 1.282 0.579
D99% 6441.1±108.7 6358.2±75.5 82.9±44.9 1.29±0.38 1.334 0.539
CTVnd-L-P
D1% 7096.3±119.6 7039.3±138.2 57.0±29.3 0.80±0.19 0.865 0.689
Dmean 6180.4±79.4 6090.3±61.2 90.1±54.6 1.46±0.49 1.261 0.598
D99% 5107.1±99.3 5036.2±45.5 70.9±46.2 1.39±0.51 1.252 0.602
GTVnd-R-P
D1% 7136.9±144.3 6989.3±132.1 147.6±52.1 2.06±0.33 1.367 0.429
Dmean 6859.3±106.1 6780.6±99.2 78.7±51.3 1.15±0.38 1.225 0.639
D99% 6399.8±108.7 6338.2±52.6 61.8±45.3 0.96±0.29 1.246 0.632
CTVnd-R-P
D1% 7066.8±109.2 6999.2±107.2 67.6±39.4 0.96±0.37 0.361 0.753
Dmean 6170.3±66.4 6090.3±41.9 90.0±49.6 1.30±0.59 1.036 0.647
D99% 5138.9±77.3 5059.6±42.3 79.3±51.2 1.54±0.47 1.127 0.641
脊髓
D1% 3788.9±203.9 3692.6±209.6 96.3±41.1 2.54±0.81 1.349 0.448
Dmean 2109.6±144.3 2023.6±159.8 86.0±31.9 4.07±1.27 1.603 0.159
D99% 608.2±400.1 726.6±509.2 118.4±66.9 19.4±17.1 4.018 0.001
脑干
D1% 5003.1±503.9 4870.6±489.1 132.5±51.8 2.65±0.72 1.333 0.522
Dmean 2711.4±344.3 2623.6±369.8 87.8±41.3 3.23±0.97 1.594 0.203
D99% 511.2±301.3 428.3±279.1 82.9±46.2 16.2±7.6 4.035 0.001
左腮腺
D1% 5103.9±311.1 5002.7±299.3 101.2±37.8 1.98±0.66 1.356 0.436
Dmean 2783.1±356.2 2651.2±369.7 131.9±40.4 4.73±1.91 1.685 0.143
D99% 1368.4±199.3 1221.2±181.2 147.2±53.5 10.7±2.89 3.646 0.005
右腮腺
D1% 4903.1±283.1 4976.2±299.3 73.1±29.8 1.49±0.56 1.036 0.647
Dmean 2671.5±309.6 2771.6±289.5 100.1±41.3 3.75±1.33 1.471 0.248
D99% 1271.5±185.1 1111.6±169.3 159.9±31.5 12.6±3.31 4.112 0.001
左晶状体
D1% 400.9±79.6 305.3±88.3 95.6±21.2 23.8±11.4 4.328 0.001
Dmean 311.6±68.3 231.6±59.7 80.0±19.7 25.6±10.2 4.658 0.001
D99% 253.9±57.7 198.6±62.3 55.3±14.6 21.7±9.3 4.210 0.001
右晶状体
D1% 421.3±97.1 319.3±72.1 102.3±35.2 24.2±18.9 4.551 0.001
Dmean 313.3±46.3 225.6±49.2 87.7±29.1 28.0±16.7 4.896 0.001
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Study on the design and application of dechlorination device for water in dialysis/JIANG Zhong-wei, CAO 
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[Abstract] Objective: To design two kinds of dechlorination device for water used in dialysis, and to adopt the method 
of titration and neutrilization for dechlorination by anhydrous sodium sulfite so as to implement emergency treatment 
for the phenomenon that the concentration of chlorine exceeded standard in the water of dialysis. Methods: Aimed at 
the two kinds of designs of dechlorination devices, included applying original bucket to implement dechlorination and 
applying micro pump to implement dechlorination, for the water of dialysis, the titration method of anhydrous sodium 
sulfite was used to neutralize chlorine in the water when the concentration of chlorine exceeded the standard on that 
day of dialysis. After the concentration of chlorine reached the standard, through sampling at original water, soft water 
and reverse osmosis water to detect the concentration of sulfate. Results: The experiment confirmed that the applied 
concentration was 1 g/L when the concentration of chlorine exceeded standard on that day of dialysis, and the solution 
of sodium sulfite was dropped in original bucket as the speed of 38 drips/min to implement neutralization. After the 
concentration of chlorine reached the standard, the detected concentrations of sulfate at original water and soft water 
were 104 mg/L, and it was less than 5mg/L at reverse osmosis water. Conclusion: The method of neutralizing chlorine 
by the titration of anhydrous sodium sulfite can effectively emergently treat the problem that the detected chlorine 
exceeds the standard on that day of dialysis. It has important value in avoiding acute complications of patients such as 
hemolytic reaction.
[Key words] Dialysis water; Chlorine exceeding standard; Anhydrous sodium sulfite; Emergency
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血液透析是肾功能衰竭患者应用最多的一种肾
替代治疗方法，随着血液透析质量控制监管力度的不
断加强，患者的平均透析寿命逐年增长。在透析过程
中，患者一次透析需要120～150 L反渗水，一年将接受
15000～26000 L透析用水，如果透析用水中化学污染物
存在超标，将会引起患者呕心、呕吐、溶血、贫血等急
慢性透析并发症，严重者可危及生命[1]。因此对透析用
水有极高的化学纯净度要求，以确保透析安全。
近年来，国内外有关透析用水氯超标导致的不良
事件屡有报道，至今除了及时更换活性炭尚无有效的
方法解决此类问题。为此，本研究针对透析当日检测
透析用水氯超标时通过滴定亚硫酸钠溶液的方法予以
